Markets
markets
Luke Kawa

Why CoreWeave announcing the date of its Q2 earnings actually matters

CoreWeave, the recently IPO’d provider of access to Nvidia’s GPUs, announced on Wednesday that it will be releasing earnings on August 12 after the market closes.

Normally, we would not write about companies telling us when they’re publishing quarterly results. But this situation is not normal.

As previously detailed, CoreWeave’s prospectus indicates that the lockup period for 84% of its shares expires on “the close of trading on the second trading day after the date that we publicly announce earnings for the second quarter.”

Now, it’s not like CoreWeave’s major holders are going to be eagerly waiting for the close of trading on August 14 with both hands hovering over the sell button, ready to flood the market. But it is highly likely that the float going up will make the cost of borrowing CoreWeave go down, since there’s going to be more shares available to sell short.

That’s certainly something that matters to people who either a) want to bet against the high-flying AI darling and, perhaps more importantly, b) those who want to bet on a successful CoreWeave-Core Scientific merger.

The cost to short CoreWeave and buy Core Scientific to profit from the big spread between where the latter was trading versus the former was prohibitively high.

And lo and behold, after CoreWeave tells the world when its Q2 earnings will drop, we’re seeing a session where shares of Core Scientific manage to rise while shares of the acquiring company fall.

More Markets

See all Markets
markets

IREN drops on convertible debt offering

Shares of crypto miner and AI compute provider IREN dropped after the Australia-based, US-listed company said late Tuesday that it would sell $875 million in convertible senior debt.

The announcement came late in the trading day and caused a sell-off in the aftermarket session that continued into Wednesday trading.

The offering makes sense; the company can probably get some fairly cheap capital after its shares doubled over the last month.

But it exposes shareholders to some dilution risk if buyers of the hybrid securities do convert them into equity, which explains the market reaction.

The offering makes sense; the company can probably get some fairly cheap capital after its shares doubled over the last month.

But it exposes shareholders to some dilution risk if buyers of the hybrid securities do convert them into equity, which explains the market reaction.

markets

Tempus AI shares surge to all-time high

Shares of Tempus AI jumped over 7% Wednesday to reach an all-time high of $99.90. Shares of the AI medical diagnostics company are up over 191% for the year so far.

The company has recently announced a flurry of FDA clearances for its technologies. Most recently, on September 22, Tempus AI was granted FDA clearance for its Tempus xR IVD device, which is used to tailor cancer therapies.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.